Immatics NV (IMTX) Stock AnalysisIMTXImmatics NV

Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Immatics NV (IMTX) is not a good buy right now due to its current price of $6.73, which is significantly below the analyst price target of $17. The stock has a very low RSI of 24.654, indicating it is oversold, but the negative momentum and ongoing financial losses raise concerns. The company reported a net income loss of €62.49 million in Q2 2026, which reflects serious profitability challenges. Additionally, the stock has seen a year-to-date change of -35.60%, indicating a downward trend that may continue in the near term. The main risk is the ongoing financial losses, which could further depress the stock price.